Focused ultrasound: DeepBrain’s approach
DeepBrain is developing non-invasive focused ultrasound neuromodulation with smartphone-guided placement and adaptive monitoring. This overview describes the intended approach and the boundaries of the current public demonstration.
DeepBrain is a pre-launch research project. It is not currently a medical device available to buy. Clinical performance figures on this site are design targets pending clinical confirmation.
Placement, targeting and adaptation
The proposed workflow has three parts. First, a smartphone guides headset placement. Second, the system aims to focus stimulation on a selected brain region. Third, a closed loop is intended to use biosignals to inform how stimulation is adjusted.
DeepBrain’s development plans bring together focused ultrasound, positioning guidance and AI personalisation. The site describes EEG and heart-rate variability as signals for the intended adaptive workflow. These are features of the design direction, rather than a claim that clinical effectiveness has been demonstrated.
What the interactive atlas shows
The interactive brain atlas lets visitors rotate an illustrative model, select the thalamus, subgenual region or amygdala, and explore the displayed focal-depth and intensity controls. It explains the targeting concept.
The atlas is not a clinical scan, a treatment simulator or a prescription. Its numerical readouts are illustrative design targets. Selecting a region in the demonstration does not establish that stimulating that region is suitable for any individual.
Clinical evidence comes next
The published roadmap moves from clinic validation to a clinical pilot and, later, supervised home use. Clinical evidence, safety monitoring and the regulatory pathway remain part of that development work. Home use is an intended future stage, not an available treatment offered by this website.
The design includes dose ceilings, monitoring and clinician oversight. Those safeguards describe what the team intends to build and evaluate; they do not replace clinical validation.
Who is developing the technology?
The public team spans AI and neuromodulation, brain-network science, biomedical engineering and business development. Read the team profiles and the development roadmap for the current public account.
For development updates, visit DeepBrain on LinkedIn or use the website waitlist. The waitlist is for updates and pilot opportunities, not a promise of treatment or device availability.